Colorectal Cancer – Pipeline Review, H1 2018 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Colorectal
Cancer – Pipeline Review, H1 2018”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

This report provides comprehensive information on the therapeutics under
development for Colorectal Cancer (Oncology), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key
players involved in therapeutic development for Colorectal Cancer and
features dormant and discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II,
Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5,
1, 27, 132, 157, 16, 185, 32 and 14 respectively. Similarly, the
Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed,
Preclinical and Discovery stages comprises 1, 23, 9, 1, 30 and 3
molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Key Topics Covered

1. Introduction

2. Colorectal Cancer – Overview

3. Colorectal Cancer – Therapeutics Development

4. Colorectal Cancer – Therapeutics Assessment

5. Colorectal Cancer – Companies Involved in Therapeutics Development

6. Colorectal Cancer – Drug Profiles

7. Colorectal Cancer – Dormant Projects

8. Colorectal Cancer – Discontinued Products

9. Colorectal Cancer – Product Development Milestones

Companies Featured

  • 3-V Biosciences Inc
  • 3SBio Inc
  • 4SC AG
  • Allinky Biopharma
  • Amarin Corp Plc
  • amcure GmbH
  • Amgen Inc
  • ARMO Biosciences Inc
  • Bionomics Ltd
  • Bionovis SA
  • Biotecnol Ltd
  • Biothera Pharmaceutical Inc
  • Cleveland BioLabs Inc
  • Idera Pharmaceuticals Inc
  • Ignyta Inc
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc
  • Kazia Therapeutics Ltd
  • Kura Oncology Inc
  • Laboratorio ELEA SACIF y A
  • LipoMedix Pharmaceutical Inc
  • Loxo Oncology Inc
  • Luye Pharma Group Ltd
  • Merck & Co Inc
  • Merck KGaA
  • Merus NV
  • MetaMax Ltd
  • Millennium Pharmaceuticals Inc
  • Mirati Therapeutics Inc
  • Moderna Therapeutics Inc
  • Molecular Partners AG
  • SynDevRx Inc
  • TaiwanJ Pharmaceuticals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • and many, many more…

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/cc3dwt/colorectal_cancer?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Colon
Cancer Drugs